CoChat

Possibilities and challenges for developing a successful vaccine for leishmaniasis

Open access

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Abstract

Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with approximately 350 million people worldwide at risk and more than 1.5 million infections occurring each year. Leishmaniasis has different clinical manifestations, including visceral (VL or kala-azar), cutaneous (CL), mucocutaneous (MCL), diffuse cutaneous (DCL) and post kala-azar dermal leishmaniasis (PKDL). Currently, the only mean to treat and control leishmaniasis is by rational medications and vector control. However, the number of available drugs is limited and even these are either exorbitantly priced, have toxic side effects or prove ineffective due to the emergence of resistant strains. On the other hand, the vector control methods are not so efficient. Therefore, there is an urgent need for developing a safe, effective, and affordable vaccine for the prevention of leishmaniasis. Although in recent years a large body of researchers has concentrated their efforts on this issue, yet only three vaccine candidates have gone for clinical trial, until date. These are: (i) killed vaccine in Brazil for human immunotherapy; (ii) live attenuated vaccine for humans in Uzbekistan; and (iii) second-generation vaccine for dog prophylaxis in Brazil. Nevertheless, there are at least half a dozen vaccine candidates in the pipeline. One can expect that, in the near future, the understanding of the whole genome of Leishmania spp. will expand the vaccine discovery and strategies that may provide novel vaccines. The present review focuses on the development and the status of various vaccines and potential vaccine candidates against leishmaniasis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13071-016-1553-y

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Vaccines against leishmaniasis
Fig. 1 Vaccines against leishmaniasisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 140 references

Cited by

See all 214

Metadata

Authors
Srivastava, S., Shankar, P., Mishra, J., & Singh, S.
Affiliations
All India Institute of Medical Sciences (IN)
Corresponding author
Singh, Sarman
Venue
Parasites & Vectors
Published
2016-05-12
Volume
9
Issue
1
Pages
277-277
ISSN
1756-3305 (ISSN-L)
OpenAlex
W2385321340
Cited by
201
References
139
Citations by year
2026: 10 · 2025: 15 · 2024: 18 · 2023: 15 · 2022: 22 · 2021: 34 · 2020: 20 · 2019: 22 · 2018: 18 · 2017: 25 · 2016: 2
FWCI
3.31
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Parasites & Vectors (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
European Commission, FP7 (Grant No. 602773 (HEALTH-F3-2013-602773) under the category FP7-Health-2013-Innovation)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Research on Leishmaniasis Studies
  • Health Sciences › Medicine › Infectious Diseases › Leprosy Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › Brucella: diagnosis, epidemiology, treatment
Keywords
leishmaniasis, Leishmania, vaccine development, vaccine candidate, neglected tropical diseases, visceral leishmaniasis, cutaneous leishmaniasis, mucocutaneous leishmaniasis, diffuse cutaneous leishmaniasis, post-kala-azar dermal leishmaniasis, live attenuated vaccine, inactivated vaccine, whole genome sequencing, drug resistance
MeSH terms
Animals, Dog Diseases, Dogs, Humans, Leishmania, Leishmaniasis, Vaccines, Attenuated, Vaccines, Inactivated, Leishmaniasis Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Possibilities and challenges for developing a successful vaccine for leishmaniasis. https://app.cochat.ai/papers/10.1186/s13071-016-1553-y
The paper
Srivastava, S., Shankar, P., Mishra, J., & Singh, S. (2016). Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasites & Vectors. https://doi.org/10.1186/s13071-016-1553-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.